Aug 2, 2022

• Efficacy data with T-DXd from the DESTINY-Breast04 trial for patients with HER2-low breast cancer; incidence and biologic relevance of HER2 mutations in breast cancer (0:00)
• Current and potential clinical roles for liquid biopsy in breast cancer; cardiac toxicity with T-DXd in the DESTINY-Breast04 trial (6:10)
• Safety profile of T-DXd from the DESTINY-Breast04 trial (11:09)
• Incidence and management of interstitial lung disease caused by T-DXd (14:54)
• Disease- and patient-specific factors and other considerations in the sequencing of chemotherapy, antibody-drug conjugates, tyrosine kinase inhibitors, SERDs (selective estrogen receptor degraders) and CDK4/6 inhibitors for breast cancer (21:45)
• Case: A woman in her early 60s with new lobular Stage II breast cancer 20 years after previous breast cancer on the same side (28:39)
• Case: A woman in her late 20s with a right breast lump and a strong family history of breast cancer (36:12)
• Case: A woman in her late 30s presenting with right axillary pain who experiences disease progression on T-DM1 and then receives T-DXd (46:09)
• Future of novel antibody-drug conjugates alone and in combination with immunotherapy for breast cancer (52:35)

CME information and select publications